Saxagliptin can not be used in patients with type 1 diabetes or diabetic ketoacidosis. A study of the combination of salatrine and insulin has not been performed.
The clinical trial data of patients with moderate to severe renal insufficiency are limited and are not recommended for use in such populations (see usage and pharmacokinetics).
Saxagliptin is used by patients with impaired liver function to be cautious and not recommended for patients with severe hepatic insufficiency (see usage and pharmacokinetics).
The following adverse reactions have been reported during the use of saxagliptin: severe hypersensitivity (including rapid onset of allergic reactions and angioedema). Since these adverse reactions are spontaneous reporting, the population from the sample size is uncertain and therefore can not reliably estimate the incidence of these adverse reactions. If there is a serious hypersensitivity to the presence of saxagliptin, discontinue use, assess whether there are other possible causes, and switch to other programs to treat diabetes (see taboo and adverse reactions "post-marketing experience").
There are reports of monkeys in the non-clinical toxicology test found that monkeys have ulcers and necrotic skin lesions (see Pharmacology and Toxicology). Although the incidence of skin lesions was not found to be clinically elevated, the clinical experience of using shagudine was limited in patients with diabetes complicated with skin lesions. The post-marketing report showed a rash in patients with DPP4 inhibitors, and the rash was also listed as one of the adverse effects of saxagliptin (see adverse reactions). In the daily management of diabetic patients, it is recommended) to observe the presence of blisters, rash and ulcers.
The clinical experience is limited in patients with NYHA class I-II, and there is no clinical experience with the use of sagreline in patients with IHA-NYHA.
The Saxagliptin clinical trial did not study patients with organ dysfunction or who were diagnosed with immunodeficiency syndrome who were diagnosed with immunodeficiency syndrome. Thus, the effectiveness and safety of saxagliptin in such patients has not been achieved.
Saxagliptin contains lactose monohydrate. Rare galactose intolerance of genetic disease, Lapp lactase deficiency or glucose - galactose malabsorption in patients who are not taking Anrze.
With drugs that are known to cause hypoglycemia
Insulin secretagogues (such as sulfonylureas) can cause hypoglycemia. Therefore, when combined with shagudite, the need to reduce the dose of insulin secretagogues to reduce the risk of hypoglycemia.
Study on the end point of vascular risk
There is currently no conclusive clinical study demonstrating that saxagliptin or any other diabetes medication can reduce the risk of macrovascular complications.